[OA-23] Tropomyosin receptor kinase protein expression in Thai cholangiocarcinoma: clinicopathological correlation, pattern expression and prognosis
Pimpika Leepisuth, Sasithorn Watcharadetwittaya and Prakasit Sa-ngiamwibool
Department of Pathology, Facolty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Tropomyosin receptor kinase (TRK) gene fusion has been found in associated with many tumours and coold be targeted treatment. Immunohistochemistry (IHC) expression of TRK is widely used to screening this alternation. The aim of this study was to investigate the expression of TRK protein detected by IHC in Thai cholangiocarcinoma (CCA) and to correlate with clinicopathological and survival data. Retrospective study of CCA patients who diagnosed from January 2011 to December 2015. A total of 85 CCA patients were enrolled. The TRK IHC was expressed in 26 cases (31%) and most of them (25 cases, 96.2%) showed cytoplasmic expression with focal and weak intensity. No clinicopathological correlation with TRK IHC expression was observed. The median survival time of the positive and negative TRK IHC groups were 1.88-year and 1.30-year, respectively (p = 0.041) with hazard ratio 0.564 (p = 0.039, 95% CI = 0.328 – 0.971). In conclusion, the TRK IHC is wildly available, rapid, and high sensitivity but the confirmatory testing is necessary in tumours with low incidence of NTRK gene fusion.
Keywords: cholangiocarcinoma; immunohistochemistry; prognosis; tropomyosin receptor kinase